Resistance to cancer therapies has been a long-standing challenge in cancer treatment [10], and resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) has been the primary cause of cancer recurrence and treatment failure in patients with EGFR-mutant non-small-cell lung cancer (NSCLC) [11]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.